IRTC - iRhythm Technologies, Inc.
TransMedics Group (NASDAQ: TMDX - Get Free Report) and iRhythm Technologies (NASDAQ: IRTC - Get Free Report) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability. Institutional and Insider Ownership 99.7% of TransMedics
SAN FRANCISCO, Oct. 15, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will release financial results for the third quarter 2026 after the close of trading on Thursday, November 5, 2026. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy claims arising from a reported data breach at iRhythm Holdings, Inc.
What happened On October 5, 2026, iRhythm Holdings, Inc. (NASDAQ: IRTC) said it completed its previously announced acquisition of Vital Connect, Inc. The buyer was iRhythm Technologies, Inc., iRhythm's direct wholly owned subsidiary. Vital Connect is now a wholly owned subsidiary of that unit and an indirect subsidiary of iRhythm Holdings, Inc. The purchase included
SAN FRANCISCO, Oct. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC) today announced that it completed the previously announced acquisition of Vital Connect, Inc. ("VitalConnect"), a leader in wearable biosensor technology and ambulatory cardiac monitoring.
Following completion of the forensic investigation, company begins notifying impacted individuals Following completion of the forensic investigation, company begins notifying impacted individuals
NEW YORK, Sept. 27, 2026 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of iRhythm Technologies, Inc. (NASDAQ: IRTC) breached their fiduciary duties to shareholders.
iRhythm's Q2 momentum, AI-driven predictive care and deeper EHR integration support growth, though reimbursement pressures remain.
Hsbc Holdings PLC acquired a new position in shares of iRhythm Technologies (NASDAQ: IRTC) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 4,473 shares of the company's stock, valued at approximately $528,000. Other institutional investors have also recently bought and sold
California State Teachers Retirement System raised its stake in iRhythm Technologies (NASDAQ: IRTC) by 13,944.0% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 5,241,770 shares of the company's stock after purchasing an additional 5,204,446 shares during the quarter. California
iRhythm's Q2 revenue growth, margin expansion and record free cash flow strengthen its case, but reimbursement and regulatory risks remain elevated.
SAN FRANCISCO, Aug. 26, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference.
iRhythm Technologies is evolving from a cardiac patch producer to a comprehensive cardiac monitoring platform, leveraging software and workflow integration for a competitive advantage. Q2 2026 marked a financial inflection: 20.1% revenue growth, 72.8% gross margin, and adjusted EBITDA margin expansion to 19.3%, with raised full-year guidance and record free cash flow. The ZEUS platform's FDA clearance enables significant margin leverage, reducing clinician review time by 50% and targeting $100 million in cost savings over five years.
Did iRhythm Technologies, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, Aug.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
IRTC's VitalConnect deal expands its cardiac monitoring reach across ambulatory, inpatient and hospital-to-home care while opening new growth opportunities.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bank of America Corp DE trimmed its holdings in iRhythm Technologies (NASDAQ: IRTC) by 41.7% in the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 432,539 shares of the company's stock after selling 309,231 shares during the period. Bank of America Corp DE owned approximately 1.32% of
IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.